AEZS News and Press, Aeterna Zentaris Inc. From 05/11/22

Aeterna Zentaris press release (NASDAQ:AEZS): Q1 GAAP EPS of -$0.02. Revenue of $1.5M (-11.8% Y/Y). The company ended the quarter with $63.6M in cash, expected to fund operations through 2023. For further details see: Aeterna Zentaris GAAP EPS of -$0.0...

– C ontinue d advancement across di versified development pipeline – Company ended the quarter with $ 6 3 . 6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, M...

– Company advancing development of its Autoimmunity Modifying AIM Biologic al s as a potential therapeutic treatment option for Parkinson’s Disease (" PD "), a neurodegenerative movement disorder TORONTO, ON...

Aeterna Zentaris (NASDAQ:AEZS) said the European Patent Office issued a patent related to use of macimorelin to diagnose growth hormone deficiency (GHD) in adults. The company said macimorelin is an orally active small molecule that stimulates the secretion of growth hormone (GH) from th...

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin ® / Macrilen ™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April...

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor S...

– Live moderated video webcast fireside chat with Dr. Klaus Paulini , CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday , April 14th at 10 :00 AM ET TORONTO, ONTARIO, April 12, 2022 (GLOBE NEWSWI...

– Company to present regarding AIM Biologic al s as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE...

Aeterna Zentaris press release (NASDAQ:AEZS): Q4 GAAP EPS of -$0.02 in-line. Revenue of $1M (-58.3% Y/Y) beats by $0.37M The Company had $65.3 million in cash and cash equivalents at December 31, 2021. Shares +2.78% PM. For further details see: Aeterna Zentaris GAAP EPS of -$0.02 in-lin...

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) -- Aeterna...